You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Nanoparticle Delivery System for Ewing Sarcoma Treatment

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    DESCRIPTION provided by applicant This Phase I STTR project seeks to demonstrate proof of principle that novel targetable nanoparticles can delivery therapeutic substances to human tumor cells and reduce tumor burden in metastatic cancer The concept for these nanoparticles is based on the polymerized liposome nanoparticle PLN that displays functional antibodies that target tumor cell surfac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: NIGMS

    DESCRIPTION provided by applicant The long term goal of this Phase I STTR project is to develop a commercially viable ultrasound contrast reagent UCR that will allow the noninvasive identification of newly forming abdominal adhesions after surgery Successful implementation would have significant impact because we would remove the impediment to clinical testing of anti adhesion therapies and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary Abstract DermaXon s project goal is to develop efficacious novel selective inhibitors of CYP A for the topical treatment of ichthyosis Congenital ichthyosis is a family of hereditary disorders of keratinization characterized by dry scaling skin that may be thickened or very thin impacting the quality of life of patients and their family members Currently there is no cure f ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel antibacterial agents derived from natural products

    SBC: Promiliad Biopharma Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease The resistance problem is compounded by the lack of discovery of new antibiotics especially those with novel mechanisms of action New antibiotics are critically needed as resistance to recently developed antibiot ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Optimized Endectocide-treated Bird Feed Formulations for West Nile Virus Control

    SBC: TDA RESEARCH, INC.            Topic: NIAID

    Project Summary Abstract Development of Optimized Endectocide treated Bird Feed Formulations for West Nile Virus Control STTR Phase I Application PIs Brady Clapsaddle TDA Research Inc Dr Brian Foy Colorado State University West Nile Virus WNV is the leading cause of domestically acquired arboviral disease in the United States resulting in significant disease and death every year in both ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC.            Topic: NIA

    The United States has the highest rate of incarceration in the world There are over state and federal prisons housing over million prisoners in the United States The demographics of the prison population are shifting Longer sentences and constrained options for early release compound this trend The older adult segment of prison populations has more than tripled since The health ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer

    SBC: ACTORIUS PHARMACEUTICALS, LLC            Topic: 100

    DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government